Nureca Limited has submitted an investor presentation for the third quarter of fiscal year 2026 (Q3 FY26), following the release of its un-audited standalone and consolidated financial results. The presentation details the company's financial performance for the quarter ended December 31, 2025.

The company reported significant year-on-year growth in its financial metrics. Revenue from operations for Q3 FY26 stood at ₹540 million, marking a 27% increase from ₹425 million in Q3 FY25. For the nine-month period ending December 31, 2025 (9M FY26), revenue from operations reached ₹1536 million. EBITDA for Q3 FY26 grew by 314% year-on-year to ₹54 million, compared to ₹25.4 million in Q3 FY25. Profit After Tax (PAT) for Q3 FY26 was ₹37 million, a 233% increase from a loss of ₹28 million in Q3 FY25.

The presentation also emphasized Nureca's strategic pillars, including D2C growth, omnipresence through an expanding offline distribution network, in-house manufacturing capabilities, and connected health solutions via the Dr Trust 360 platform. The company highlighted its digital-first approach, with over 90% of revenue generated through online sales. Nureca is a debt-free company with a healthy liquidity position.

The company's flagship brand, Dr Trust, has received numerous accolades, including recognition as India's number one brand in Home Healthcare and Wellness. The presentation also provided market size projections for various healthcare products in India and neighboring countries, indicating significant growth potential. Nureca is focused on leveraging consumer insights, optimizing its supply chain, and expanding its product portfolio and distribution channels to drive future growth.